BACKGROUND AND PURPOSE: International consensus reports recommend postmastectomy radiotherapy only to patients at high risk of a local recurrence (LR). MATERIALS AND METHODS: The present analysis included 1000 out of 3083high-risk breast cancer patients randomly assigned to postmastectomy radiotherapy in the DBCG82 b&c trials. Tissue microarrays had been constructed and sections stained for estrogen, progesterone and HER2 receptors. Median potential follow-up time was 17 years. Endpoints were LR as isolated first event, breast cancer mortality and overall mortality. RESULTS: Among patients randomly assigned to not receive radiotherapy, three prognostic subgroups of LR risk were found. "The good" defined by at least four out of five favorable criteria (3 positive nodes, tumor size <2cm, Grade 1 malignancy, estrogen or progesterone receptor positive, HER2 negative), "the Poor" defined by at least two out of three un-favorable criteria (>3 positive nodes, tumor size >5cm, Grade 3 malignancy) and finally "the Intermediate" the group in between. The smallest absolute reduction in 5-year LR probability (11%) after radiotherapy was seen for the good prognosis group. A similar absolute reduction in 15-year breast cancer mortality after radiotherapy (11%) was seen. The largest absolute reduction in 5-year LR probability after radiotherapy was seen for the poor prognosis group (36%). However, this large LR reduction did not translate into any reduction in 15-year breast cancer mortality (0%). CONCLUSION: Translation of LR reduction into breast cancer mortality reduction after postmastectomy radiotherapy to high-risk breast cancer patients seems to be heterogeneous, with the largest translation occurring within the good prognosis group.
RCT Entities:
BACKGROUND AND PURPOSE: International consensus reports recommend postmastectomy radiotherapy only to patients at high risk of a local recurrence (LR). MATERIALS AND METHODS: The present analysis included 1000 out of 3083 high-risk breast cancerpatients randomly assigned to postmastectomy radiotherapy in the DBCG82 b&c trials. Tissue microarrays had been constructed and sections stained for estrogen, progesterone and HER2 receptors. Median potential follow-up time was 17 years. Endpoints were LR as isolated first event, breast cancer mortality and overall mortality. RESULTS: Among patients randomly assigned to not receive radiotherapy, three prognostic subgroups of LR risk were found. "The good" defined by at least four out of five favorable criteria (3 positive nodes, tumor size <2cm, Grade 1 malignancy, estrogen or progesterone receptor positive, HER2 negative), "the Poor" defined by at least two out of three un-favorable criteria (>3 positive nodes, tumor size >5cm, Grade 3 malignancy) and finally "the Intermediate" the group in between. The smallest absolute reduction in 5-year LR probability (11%) after radiotherapy was seen for the good prognosis group. A similar absolute reduction in 15-year breast cancer mortality after radiotherapy (11%) was seen. The largest absolute reduction in 5-year LR probability after radiotherapy was seen for the poor prognosis group (36%). However, this large LR reduction did not translate into any reduction in 15-year breast cancer mortality (0%). CONCLUSION: Translation of LR reduction into breast cancer mortality reduction after postmastectomy radiotherapy to high-risk breast cancerpatients seems to be heterogeneous, with the largest translation occurring within the good prognosis group.
Authors: L Livi; I Meattini; V Scotti; C Saieva; G Simontacchi; L Marrazzo; C Franzese; S Cassani; F Paiar; V Di Cataldo; J Nori; L Jose Sanchez; S Bianchi; L Cataliotti; G Biti Journal: Radiol Med Date: 2011-03-07 Impact factor: 3.469
Authors: Y M Kirova; P Castro Pena; R Dendale; V Servois; M A Bollet; N Fournier-Bidoz; F Campana; A Fourquet Journal: Br J Radiol Date: 2009-12-17 Impact factor: 3.039
Authors: Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King Journal: Curr Probl Surg Date: 2016-11-29 Impact factor: 1.909
Authors: Birgitte V Offersen; Hans-Jürgen Brodersen; Mette M Nielsen; Jens Overgaard; Marie Overgaard Journal: Breast Care (Basel) Date: 2011-10-13 Impact factor: 2.860
Authors: Maria Cristina Leonardi; Ida Rosalia Scognamiglio; Barbara Alicja Jereczek-Fossa; Giovanni Corso; Patrick Maisonneuve; Samantha Dicuonzo; Damaris Patricia Rojas; Maria Alessia Zerella; Anna Morra; Marianna Alessandra Gerardi; Mattia Zaffaroni; Alessandra De Scalzi; Antonia Girardi; Francesca Magnoni; Emilia Montagna; Cristiana Iuliana Fodor; Viviana Enrica Galimberti; Paolo Veronesi; Roberto Orecchia; Roberto Pacelli Journal: Breast Cancer Res Treat Date: 2021-04-27 Impact factor: 4.872